Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (May 2013)
48 slides from Fluoropharma Medical's investor presentation, May 7, 2013
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Fluent _— Pharma Enabling Personalized Medicine Through Precision Diagnostics.
Slide 2: Forward-Looking Statements
FIUOrO. = Forward-Looking Statements 2 Pharma This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be cove
Slide 3: Patients will die of heart disease
Patients will die of heart disease A cardiac perfusion scan is performed Portfolio of compounds in heart disease CardioPET BFPET VasoPET www.FluoroPharma.com Ww
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Next generation molecular imaging drugs for diagnostic testing BFPET m
Slide 5: Investment Highlights
Investment Highlights Proprietary products that support new technologies for personalized medicine ¢ Next generation / first-in-class diagnostic imaging ¢ Helps determine the course of cardiac treatment Two Phase Il-ready products with short study timelines, both directed to very large markets ¢ BFP
Slide 6: Product programs and potential patients
|= 12 million potential patients = For use in combination with stress-testing in patients with presumptive chronic CAD = To replace SPECT in institutions with PET capability = Phase 2 (U.S., China) = Launch 2016 = U.S. patent through 2025 Perfusion images 17 million potential patients Detects region
Slide 7: Clinical drivers advancing the transition to PET in clinical cardiology
Clinical drivers Advancing the Transition to PET in Clinical Cardiology FIUOrO. = Pharma Drivers and Benefits: (A) Expansion of clinical indications/clinical needs Lower radiation dose Improved diagnostic accuracy Improved patient outcomes © continued advancements in scanner technology Fusion of ana
Slide 8: O1O0I
O1O0I View size. (OU . SOC 44 Wwe 227 j a, Fy . | MHA sac lar None fe Fa Fa R Lu u K ™ Zoom: 76% Angle | USAGE im: 1/16 3/8/13 11:38:03 AM Uncompressed EEL ‘MEVLA Made In Osirix
Slide 9: Technical Trends - Growth drivers enabling shift in technology
Technical Trends - Growth drivers enabling shift in technology Fluoro -— Technical and Diagnostic Benefits of PET vs. SPECT Y-Aaeharma ¢ Improved overall image quality ¢ Dynamic tomographic imaging ¢ High Definition Hybrid imaging: calcium scoring, CT angiography ¢ Improved spatial, temporal and con
Slide 10: Global Market for PET/SPECT (2010-2020)
Global Market for PET/SPECT (2010-2020) PET new unit sales projected to exceed SPECT a) 7000 10 6000 8 5000 4000 6 3000 4 2000 2 1000 0+ r T ss T T — o + a__- r _ ' 1 — 1 2010 2011 2012 2013 2014 2015 2016 2010 2011 2012 2013 2014 2015 2016 eoa9 —=PET ——specT || 600 | 7000 6000 = 5000 400 + 4000 A00
Slide 11: PET Predicted to grow to 1/3 of U.S. nuclear cardiology procedures
PET Predicted to grow to 1/3 of ee U.S. nuclear cardiology procedures Approximate Use of Cardiac Diagnostic Testing i] Future of ear Cardiology in 2020 i 100% 5 ; 90% + : 80% | } |! 70% + ' SPECT & 1 SPECT/CT 60% + ' (- i 50% + ! 40% + 30% + 20% + 10%} 44% 2% 0% 4 ‘ = Q e 5! g z \ PET & PET/CT = 2 2
Slide 12: Why PET now
Why PET now: F lUrelte eel Distribution, infrastructure and increased install base — Pharma ¢ PET has a significantly higher rate of specificity and sensitivity than SPECT ¢ Leads to decreased attenuation artifacts and fewer inconclusive studies ¢ Provides a more accurate diagnosis for patients, pot
Slide 13: Comparison of SPECT and PET Perfusion Imaging
Comparison of SPECT and PET Perfusion Imaging Available Today 4 Panel A illustrates improved specificity with Stress .@) : PET. A fixed defect in the inferior wall on SPECT is absent on PET, suggesting the presence of a SPECT attenuation artifact. a { B Panel B illustrates improved sensitivity with
Slide 14: Large, Growing Market for Imaging Agents
Large, Growing Market for Imaging Agents * Global market projected to exceed $15 billion by 2015 Imaging Drug Market Worldwide Sales Forecast ¢ Fueled by need for personalized medicine Womens seen 16 4 15B Total ¢ Additional drivers include: $ _ ¢ Growing volume of diagnostic examinations 12 | $78 T
Slide 15: Product Portfolio Market Size and Revenue Opportunity
Product Portfolio Market Size and Revenue Opportunity BFPET CardioPET VasoPET Patient Population 12.0m 17.4m 55.5m being Imaged Adoptio PET Procedures FPMI PET Market Share FPMI Procedures FPMI Price Per Dose Product Revenue $0.9-3.2B $0.8-2.2B $510M Opportunity Sources: Campbell Alliance & estimate
Slide 16: BFPET Clinical Use
BFPET Clinical Use MYOCARDIAL PERFUSION IMAGING ¢ Evaluate patients with known or suspected CAD ¢ Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST ¢ Perfusion imaging with SPECT tracers (e.g. MIBI, tetrophosmin, TI-201) or Rb-82 CLINICAL NEE
Slide 17: BFPET Phase I Trial Findings
BFPET Phase | Trial Findings Results show excellent perfusion BFPET Phase la completed imaging properties ¢ Rapid extraction from blood ¢ Stable heart uptake over time ¢ High target to background ratios ¢ Convenient imaging window oane ¢ Whole body effective dose: 73.54 17.59 mrem/mCi ¢ 12 healthy v
Slide 18: FLA ENSPITAL W/L PLA HOSPITAL ‘FLA HOSPITAL a |
FLA 501 ENSPITAL W/L PLA 301 HOSPITAL ‘FLA 301 HOSPITAL a | hae haa haan | Pour t 7 Par Pour iste | 5% Soa a Rare | SoeaT-09 | fe Li 7 | ] ' 5.0m ih 5.0m wan wa eo mae0 cr @st 88) PET (20386: 05536)CT G57: 680 PET = SOX PLA S01 EISPITAL ‘ PLA S01 HOSPITAL Yinedia \ Yost sm2i6 ry 4 _ ner | 2 FET Gosn
Slide 19: FLA ENSPITAL PLA HOSPITAL ‘FLA HOSPITAL a
FLA 501 ENSPITAL PLA 301 HOSPITAL ‘FLA 301 HOSPITAL a Yokinedi Yinedia Yekinedia VI rosy Yr oeer Yost SES816 SES816 Brana) 22-07-09 4.0m 4.0m was wasn 30 m0 i . cr 80 95) PET (45836:65536)CT (650: 55)OP ERT = SOM a 01 Boer HA 903 RSP = heat : Es haa ror | J Pear foot Esme 4 Rare Ritts \ v 4.0m was B
Slide 20: The BFPET Opportunity
The BFPET Opportunity . Projected BFPET Scans Assumptions MILLIONS 14 5 Est. 5" Year Revenue iL | $691 million Est. PET “ty . st. Market Patients Market Size as 4 Myocardial 06 4 perfusion 12 million 3.6 million imaging 0.4 5 0.2 + 0.0 + Year 1 Year 3 Year 5 20 www.FluoroPharma.com
Slide 21: ‘SUPINE
‘SUPINE -@ oO oO ‘STRESS_FEP SUPINE ee es o « REST_FBP Boo; <-- Apical Short Ais Basal SUPINE » b S é STRESS | SUPINE i: 4 > > g REST J <---Septal Vertical Axis Lateral SUPINE SUPINE en SPECT BFPET
Slide 22: CardioPET Clinical Use
CardioPET Clinical Use CARDIAC VIABILITY ASSESSMENT ¢ Identify patients that may benefit from PCI or revascularization and guide intervention ¢ Evaluate CAD in patients that cannot exercise CURRENT TREATMENT ¢ Invasive coronary angiography CLINICAL NEED * 1.3 million diagnostic angiography procedure
Slide 23: CardioPET Phase I Results
CardioPET Phase | Results 18F @ sete Aho Fatty acid analog that detects regions of metabolic insufficiency (15 NHV and 6 CAD patients) ¢ CardioPET promising safety with no AEs detected * Clinical findings consistent with MPI SPECT ¢ Quality of CardioPET images substantially superior to MPI SPECT Nor
Slide 24: Transverse
Transverse MPR Coronal MPR Transverse MPR t R76_ dynamic (AC) Perfusion ee ee Apex
Slide 25: Dataset-2_ Frame: Ung
Dataset-2_ Frame: Ung 22.0 Normalized Map Nn “ 28:3 2
Slide 26: The CardioPET Opportunity
The CardioPET Opportunity Projected CardioPET Scans MILLIONS 2.0 4 Est. 5" Year Revenue $605 million 16 4 . Este Est. FP Market Patients Marersize Snare 2 CAD diagnosis a a 5 at rest 3.8 million 1.4 million 32% 08 4 Cardiac viability 4 million 0.5 million 80% 0.4 4 assessment Myocardial 00 J perfusi
Slide 27: VasoPET Indications and Clinical Use
VasoPET Indications and Clinical Use EVALUATION OF ¢ Patients with acute cardiac event or stroke (risk of recurring event) . Therapy following acute cardiac event or stroke (e.g., Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE * Clinical symptoms; several imaging agents in develo
Slide 28: Detection Of Inflamed Atherosclerotic Plaque
Detection Of Inflamed Atherosclerotic Plaque WHY INFLAMMATION IMAGING? ¢ Diagnosis before symptoms occur * Crucial role at all stages of atherosclerosis ¢ May aid drug development DEVELOPMENT & 5 «Preclinical testing completed ¢ IND preparation ongoing ¢ Plan to initiate Phase | proof of principle t
Slide 29: Experienced Management Team and Advisors
Experienced Management Team and Advisors Pharma H. William Strauss, MD Daniel Berman, MD Peter Conti, MD, PhD Elazer Edelman, MD, PhD Heinrich Schelbert, MD Andrew Selwyn, MD Thijs Spoor President, CEO ¢ Healthcare executive with >15 years medical industry experience ¢ Former securities analyst at J
Slide 30: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Capitalize on multiple cardiovascular molecular imaging agents for PET ¢ Cardiac viability assessment ¢ Myocardial perfusion imaging ¢ Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing ¢ Diagnostic alternativ
Slide 31: www.FluoroPharma.com ek
www.FluoroPharma.com ek
Slide 32: The Next Big Step in Healthcare
The Next Big Step in Healthcare MEDICINE TODAY One treatment fits all - => still a guessing game www.FluoroPharma.com se
Slide 33: Personalized Diagnosis
Personalized Diagnosis MEDICINE TOMORROW must be personalized a veeument rr ci Personalized medicine begins with 8 : eben pee the right diagnosis Right Time for the Right Outcome it Before you can see it, Before the patient feels it, We can identify it www.FluoroPharma.com ee
Slide 34: Unmet Need for Better Imaging Methods
Unmet Need for Better Imaging Methods FDA Warning in 2007 ¢ Nephrogenic systemic fibrosis for Gadolinium-based contrast agents 7 ccm ANATOMICAL ‘e : FDA Warning in 2007 IMAGING cy ' ¢ Deaths and serious cardiopulmonary reactions arising from marketed products None of these capture - physiology Pc -
Slide 35: PET Imaging Roots are in Oncology
PET Imaging Roots are in Oncology PET procedures by disease area 2500 4 oO 2000 + mol Cc oO a — . & Cardiology rs 1500 4 and 5 i» neurology 3 remain SF 4000 strong growth la opportunities a 500 0 2004 2005 2006 2007 2008 2009 Year HE Oncology Mi Neurology |) Cardiology 35 Source: Frost & Sullivan 20
Slide 36: Cardiovascular Disease is the Next Big Opportunity
Cardiovascular Disease is the Next Big Opportunity Total diagnostic radiopharmaceutical agents market: Cardiac imaging procedures are the greatest opportunity to switch to PET 25 - Procedures 236 (millions) a8 201 aes 19 24 BE / CAGR 20 J f \ { 07 -‘09 ( V _ PET (Total) 17.0% 15 4 > ; — ; ‘i 2 SPECT
Slide 37: FluoroPharma Enables Personalized Diagnosis
FluoroPharma Enables Personalized Diagnosis _— Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment Spatial Temporal Contrast ¢ Allows direct visual evaluation of Resolution Resolution Resolution disease on a molecular level Ultrasound <2mm Single bubb
Slide 38: Poised to Capture Cardio Diagnostics
Poised to Capture Cardio Diagnostics Cardiovascular Diagnostics PET Molecular Imaging ¢ 1-in-3 adults have some form of CV ¢ Superior image quality disease ¢ PET is a large and rapidly growing ¢ $403 billion: fully burdened cost of imaging platform CAD ¢ Increasing demand for PET ¢ ~12 million CV nu
Slide 39: Robust Portfolio On-Track
FIUOrO. = Robust Portfolio On-Track Pharma Market | Patients Drug / Indication Patent Licens Pre- IND | ll Hl NDA e clinical CardioPET $0.8-2.2B 17.4M |RNexs CAD ‘tate Cancer $0.9-3.2B 120M $510M 55.5M Vulnerable plaque coronary Carotid coronary perforation Vulnerable plaque carotid Sources: Campbel
Slide 40: The VasoPET Opportunity
The VasoPET Opportunity Projected VasoPET Scans : MILLIONS Assumptions 08 - Est. 5 Year Revenue 07 4 $408 million 06 4 Market Patients eer pel hie 0.5 5 Size 0.4 4 Screening for 50 million 300,000 atherosclerosis (0s) 5 0.2 4 Response to = 3. g million 380,000 therapy (statins) 01 4 Follow-up after
Slide 41: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare Medical
Slide 42: Molecular Imaging Commercial Landscape
Molecular Imaging Commercial Landscape 7 Drug Radio- Development é Pharmaceutical FluoroPharma Distribution Lantheus IBA Molecular Navidea ; ‘ily , ~ Eckert & Ziegler ve Cardinal Health Covidien Draxlmage Siemens/ PETNET Phillips Scanner Development Multiple players in each value chain www.FluoroPha
Slide 43: The cycle of classic medicine is reactive medical care
The cycle of classic medicine is reactive medical care Reactive Medical Care Switch Drug Again § Switch Drug Disease Severity Select Drug Diagnosis Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment 43 Personalized Medicine Coalition; Abrahams Presentation www.FluoroPharma.com
Slide 44: Shifting to outcomes focused personalized treatments increases efficiency
Shifting to outcomes focused personalized treatments increases efficiency Efficient Medical Care “Right Drug” Disease Severity Diagnosis / Prognosis. Diagnosis Screening Health Management; Molecular Screening; Early Detection; Rapid Effective Treatment; Improved Quality of Care 44 Personalized Medic
Slide 45: Cardiovascular Disease
Cardiovascular Disease KEY FACTS - US AND WW WHO: “Neglected Global Epidemic” ¢ 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. ¢ 1/3 of deaths in China, 4% in Europe ¢ 2.4M deaths US: top cause (38.5%) KEY UNMET NEEDS ¢ CAD: Get closer to the disease source - Early detec
Slide 46: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints C' mic pressures PAST FUTURE Fragmented, vy y y vy » y Integrated, non-systems > systems of of care Decisions by individual stakeholders. — . ae - elivery "Decisions by advanced stakeholder networks Predominant HCP type Solo practitioners Quality
Slide 47: Market Drivers for New PET Products
Market Drivers for New PET Products Growth in PET Low capacity Comprehensive adoption of early procedural volumes utilization diagnosis will improve utilization of technology ¢ At capacity, more patients could be ay § T diagnosed earlier leading to better patient Ss 1600 + = outcomes g = 6 Unutilize
Slide 48: Thank you for listening!
Fluent _— Pharma Thank you for listening!
FluoroPharma Medical — Investor Presentation (May 2013) on 6ix